Alcon, Inc. (ACL) Independent Director Committee Notes RiskMetrics's and Glass Lewis' Opposition to Election of Novartis Corporation (NVS)’ Designees to Alcon’s Board of Directors  
8/2/2010 7:37:26 AM

HUENENBERG, Switzerland--(BUSINESS WIRE)--The Alcon Independent Director Committee (the “IDC”) today announced that RiskMetrics Group, Inc. and Glass Lewis & Co., two global leaders in risk management, corporate governance and proxy advisory services, have both recommended that Alcon minority shareholders vote against all five of Novartis AG’s (“Novartis”) designees to the Alcon board of directors. As previously announced, pursuant to the terms of agreements between Novartis and Nestlé SA entered into in 2008, Alcon shareholders will vote on the conditional election of Novartis’ board designees at an extraordinary general meeting on August 16, 2010.